Pharmacy and Pharmaceutical Sciences
University of ManchesterPharmacy and Pharmaceutical Sciences MPhil is an undergraduate degree at University of Manchester, based in Manchester, taught full-time over 12 months.
About this course
Our PhD/MPhil Pharmacy and Pharmaceutical Sciences programme enables you to undertake a research project that will improve understanding of Pharmacy and Pharmaceutical Sciences.
Our areas of research within pharmacy and pharmaceutical sciences include:
- Development of novel nucleic acid-based diagnostics and therapeutics;
- Modelling and simulation of pharmacokinetics, drug-drug interactions and pharmacodynamics in healthy virtual populations;
- Modelling and simulation of pharmacokinetics, drug-drug interactions and pharmacodynamics in patient populations;
- Analysis of inter-individual variability in drug metabolizing enzyme activity;
- Optimal design of early phase clinical trials with new therapies and drug combinations;
- Applications of systems biology approach to prediction of drug absorption, distribution and Elimination;
- Extrapolation of in vitro data to predict in vivo pharmacokinetics and Pharmacodynamics;
- Applications of PKPD in drug development and therapeutics, particularly endocrinology, drug abuse, and paediatric pharmacology.
Study Options
This course is available in 4 study options:
Duration: 48 Months
Qualification: MPhil
Location: Manchester
Duration: 12 Months
Qualification: MPhil
Location: Manchester
Duration: 36 Months
Qualification: PhD
Location: Manchester
Duration: 72 Months
Qualification: PhD
Location: Manchester
Career Prospects
Graduates from this course typically go into the following occupations. Click through for salaries, employment rates and other UK degrees that lead there:
Related Courses
Course Details
- Qualification
- Master of Philosophy - MPhil
- Study Mode
- Full-time
- Duration
- 12 Months
- Start Date
- 2025
- Academic Year
- 2025
- Campus / Location
- Manchester
- Scheme
- Undergraduate
- Subjects
- Pharmacy, pharmacology, and toxicology
2025-entry data — 2026 offers may differ